Becton Dickinson (BDX) has been in focus for multiple reasons. On the financial performance side, the company reported strong revenue growth and Q1 2025 earnings, exceeding expectations. The company also declared and increased dividends consecutively for the 53rd year, leading analysts to regard it as a strong income stock. As part of its corporate strategy, BDX has announced the separation of its biosciences and diagnostic solutions business. The move is aimed at enhancing focus, driving growth and unlocking value. Additionally,
BDX is planning a significant investment to boost U.S. production of crucial medical devices. As per reports,
Becton Dickinson's Board of Directors authorized an additional 10 million share repurchases, completing a $750 million repurchase till date in FY25. However, over the past five years, BDX investors have not seen substantial profits, having lost 6.7% on their investments. On the personnel front, changes have been announced, with Michael Cusack named President of BD Urology and Critical Care, and Tim Patz appointed as Worldwide President of Advanced Patient Monitoring. Despite these positives, the stock fell in pre-market trading, even after beating Q1 earning forecasts.
Becton Dickinson and BDX News Analytics from Thu, 02 May 2024 07:00:00 GMT to Mon, 10 Mar 2025 09:06:45 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -6
